Effect of Gabapentin-Fluoxetine Derivative GBP1F in a murine model of depression, anxiety and cognition

Gohar, Aneela, Ali, Gowhar, Rashid, Umer, Rauf, Khalid, Arif, Mehreen, Khan, Muhammad Sona, Alkahramaan, Yasser M.S.A. and Sewell, Robert D.E. 2023. Effect of Gabapentin-Fluoxetine Derivative GBP1F in a murine model of depression, anxiety and cognition. Drug Design, Development and Therapy 17 , pp. 1793-1803. 10.2147/DDDT.S407229

Preview

PDF - Published Version Available under License Creative Commons Attribution Non-commercial. Download (3MB) | Preview

Abstract

Background and Objective: Gabapentin is a commonly prescribed antiepileptic agent for seizures, which is also used for pain and addiction management. Due to growing evidence of its abuse liability, there has been an incentive to synthesise potentially useful gabapentin derivatives devoid of adverse effects. A gabapentin adduct with a fluoxetine moiety, GBP1F, was assessed for any sedative, cognitive, anxiolytic, or antidepressant-like actions in murine behavioral models. Materials and Methods: Selected groups of mice were used for each behavioral paradigm, and the effect of GBP1F (5, 10, and 15 mg/kg) was assessed using spontaneous locomotor activity, the tail suspension test, elevated plus maze test, and the Y maze test models. Immediately following behavioral experiments, postmortem striatal and hippocampal tissues were evaluated for the effect of GBP1F on concentrations of dopamine, DOPAC, HVA, serotonin, 5-HIAA, vitamin C, and noradrenaline using high performance liquid chromatography with electrochemical detection. Results: GBP1F induced a mild suppression of locomotor activity, ameliorated anxiety and depression-like behavior, did not alter cognitive behavior, and raised serotonin and 5-HIAA concentrations in the hippocampus and striatum. GBP1F also positively enhanced dopamine and vitamin C tissue levels in the striatum. Thus, GBP1F represents a compound with anxiolytic- and antidepressant-like effects though further studies are warranted at the molecular level to focus on the precise mechanism(s) of action.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Pharmacy
Publisher:	Taylor and Francis Group
ISSN:	1177-8881
Date of First Compliant Deposit:	30 August 2023
Date of Acceptance:	26 May 2023
Last Modified:	06 Sep 2023 07:19
URI:	https://orca.cardiff.ac.uk/id/eprint/162114

Actions (repository staff only)

Edit Item